159 active not recruiting. 159 Phase 2, 50 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 159 | Active not recruiting 159 |
| Phase 1 | 50 | Active not recruiting 50 |
| Phase 3 | 9 | Active not recruiting 9 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen Arm A:Dose_dense Capecitabine in Colorectal cancer, Arm B : standard dose Capecitabine - Colorectal Cancer | Phase 2 | Active not recruiting | Sohag University | 100 | 2025-09-25 | 2025-10-14 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2025-09-11 | 2026-11-03 |
| A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection - Colorectal Cancer | Phase 2 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 103 | 2025-07-22 | 2026-08-11 |
| A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis SAR442970, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Sanofi | 105 | 2025-07-07 | 2026-11-02 |
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab - Metastatic Colorectal Cancer (mCRC) | Phase 2 | Active not recruiting | CytoDyn, Inc. | 66 | 2025-06-16 | 2026-09-09 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis D-2570, Placebo - UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | InventisBio Co., Ltd | 120 | 2025-05-22 | 2026-07-17 |
| Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab - Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC) | Phase 2 | Active not recruiting | University of Colorado, Denver | 13 | 2025-03-25 | 2025-10-02 |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | AstraZeneca | 82 | 2025-03-12 | 2026-10-22 |
| A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU - Neoplasms | Phase 2 | Active not recruiting | Blokhin's Russian Cancer Research Center | 23 | 2025-03-01 | 2025-10-02 |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain Halneuron, Placebo, Halneuron (Open Label Extension) - Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy | Phase 2 | Active not recruiting | Dogwood Therapeutics Inc. | 240 | 2025-02-21 | 2026-09-16 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors BMS-986490, Bevacizumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 360 | 2025-02-12 | 2026-09-01 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer Botensilimab, Balstilimab, Oxaliplatin - Colorectal Cancer | Phase 2 | Active not recruiting | Nicholas DeVito, MD | 16 | 2024-11-18 | 2026-02-05 |
| A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer Telisotuzumab Adizutecan - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | AbbVie | 74 | 2024-11-08 | 2026-09-23 |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Eltrekibart, Mirikizumab, Placebo - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 2 | Active not recruiting | Eli Lilly and Company | 143 | 2024-10-10 | 2026-10-07 |
| Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion Fujifilm monitoring - Colorectal Cancer, Diverticulitis of Sigmoid | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 52 | 2024-09-03 | 2026-05-20 |
Showing 20 of 159. Sign in to see all of them.
Colorectal Neoplasms (121) · Colonic Neoplasms (29) · Carcinoma, Non-Small-Cell Lung (24) · Colitis, Ulcerative (19) · Pancreatic Neoplasms (15) · Melanoma (13) · Neoplasms (13) · Stomach Neoplasms (13) · Breast Neoplasms (12) · Rectal Neoplasms (12) · Neoplasm Metastasis (10) · Endometrial Neoplasms (9) · Ovarian Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (8) · Turcot syndrome (8)
Digestive System Diseases (158) · Gastrointestinal Diseases (158) · Intestinal Diseases (158) · Digestive System Neoplasms (136) · Gastrointestinal Neoplasms (136) · Intestinal Neoplasms (136) · Neoplasms by Site (136) · Neoplasms (125) · Rectal Diseases (122) · Lung Diseases (27) · Respiratory Tract Diseases (27) · Respiratory Tract Neoplasms (27) · Thoracic Neoplasms (27) · Neoplasms by Histologic Type (24)
Bevacizumab (19) · Oxaliplatin (18) · pembrolizumab (18) · Leucovorin (15) · Capecitabine (13) · Fluorouracil (13) · Cetuximab (11) · Irinotecan (10) · Nivolumab (9) · Specimen Handling (8) · tislelizumab (8) · Biopsy (6) · Trifluridine (6) · atezolizumab (6) · Carboplatin (5)
M.D. Anderson Cancer Center (12) · National Cancer Institute (NCI) (9) · Eli Lilly and Company (4) · Memorial Sloan Kettering Cancer Center (4) · Sun Yat-sen University (4) · AstraZeneca (3) · Sanofi (3) · Seagen, a wholly owned subsidiary of Pfizer (3) · AIO-Studien-gGmbH (2) · AbbVie (2) · Akeso (2) · Alliance for Clinical Trials in Oncology (2) · Blokhin's Russian Cancer Research Center (2) · Centre Georges Francois Leclerc (2) · City of Hope Medical Center (2)
United States (107) · Canada (35) · France (34) · Spain (34) · China (31) · Italy (28) · Germany (26) · Australia (24) · South Korea (24) · United Kingdom (24) · Japan (23) · Belgium (21) · Poland (18) · Netherlands (15) · Taiwan (14)
Van K Morris (3) · Alisha Bent, MD (2) · Marwan G Fakih (2) · Abbas Chabok, MD, PhD (1) · Ajay Bansal (1) · Alexandra R Brandt-Kerkhof, MD (1)
PMID 37934000, PMID 21458303, PMID 21494121, PMID 21584903, PMID 21816436, PMID 21865946, PMID 22127070, PMID 22595848, PMID 23096768, PMID 23303141, PMID 23456389, PMID 24327518, PMID 24646562, PMID 26010778, PMID 26187751, PMID 26586415, PMID 26865277, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29118225, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30514390, PMID 30943124, PMID 30975030, PMID 31023318, PMID 31101621, PMID 31345267, PMID 31401903, PMID 31533931, PMID 31682550, PMID 31831767, PMID 31838007, PMID 31838015, PMID 31882719, PMID 31894292, PMID 31980466, PMID 32359091, PMID 32463741, PMID 32846060, PMID 32846061, PMID 32919526, PMID 33048619, PMID 33148693, PMID 33528867, PMID 33646820, PMID 33836153, PMID 33992635
2023 (14), 2015 (3), P30CA033572 (3), P30CA060553 (3), 2018 (2), 2019 (2), 2025 (2), UG1CA242609 (2), UG1CA242643 (2), 2016 (1), 2017 (1), N01CN00035 (1), N01CN00042 (1), P30CA014089 (1), P30CA015083 (1)